H2N2V1, Ncbi, Merge, bibRecord, 000B02

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Identifieur interne : 000B02 ( Ncbi/Merge ); précédent : 000B01; suivant : 000B03

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Auteurs : Mariana Baz [États-Unis] ; Myeisha Paskel [États-Unis] ; Yumiko Matsuoka [États-Unis] ; James Zengel [États-Unis] ; Xing Cheng [États-Unis] ; John J. Treanor [États-Unis] ; Hong Jin [États-Unis] ; Kanta Subbarao [Indonésie]

Source :

Journal of virology [ 1098-5514 ] ; 2015.

RBID : pubmed:25410860

Descripteurs français

KwdFr :
- Administration par voie nasale, Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Furets, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (immunologie), Modèles animaux de maladie humaine, Protection croisée, Réactions croisées, Souris de lignée BALB C, Sous-type H3N8 du virus de la grippe A (immunologie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Vaccins atténués (administration et posologie), Vaccins atténués (génétique), Vaccins atténués (immunologie).
MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués.
- génétique : Vaccins antigrippaux, Vaccins atténués.
- immunologie : Infections à Orthomyxoviridae, Sous-type H3N8 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Administration par voie nasale, Animaux, Furets, Infections à Orthomyxoviridae, Modèles animaux de maladie humaine, Protection croisée, Réactions croisées, Souris de lignée BALB C.

English descriptors

KwdEn :
- Administration, Intranasal, Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Cross Protection, Cross Reactions, Disease Models, Animal, Ferrets, Influenza A Virus, H3N8 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (genetics), Vaccines, Attenuated (immunology).
MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , genetics : Influenza Vaccines, Vaccines, Attenuated.
- immunology : Influenza A Virus, H3N8 Subtype, Influenza Vaccines, Orthomyxoviridae Infections, Vaccines, Attenuated.
- prevention & control : Orthomyxoviridae Infections.
- Administration, Intranasal, Animals, Cross Protection, Cross Reactions, Disease Models, Animal, Ferrets, Mice, Inbred BALB C.

Abstract

Equine influenza viruses (EIV) are responsible for rapidly spreading outbreaks of respiratory disease in horses. Although natural infections of humans with EIV have not been reported, experimental inoculation of humans with these viruses can lead to a productive infection and elicit a neutralizing antibody response. Moreover, EIV have crossed the species barrier to infect dogs, pigs, and camels and therefore may also pose a threat to humans. Based on serologic cross-reactivity of H3N8 EIV from different lineages and sublineages, A/equine/Georgia/1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics with the hemagglutinin and neuraminidase genes of the eq/GA/81 wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) vaccine donor virus, which is the backbone of the licensed seasonal live attenuated influenza vaccine. In both mice and ferrets, intranasal administration of a single dose of the eq/GA/81 ca vaccine virus induced neutralizing antibodies and conferred complete protection from homologous wt virus challenge in the upper respiratory tract. One dose of the eq/GA/81 ca vaccine also induced neutralizing antibodies and conferred complete protection in mice and nearly complete protection in ferrets upon heterologous challenge with the H3N8 (eq/Newmarket/03) wt virus. These data support further evaluation of the eq/GA/81 ca vaccine in humans for use in the event of transmission of an equine H3N8 influenza virus to humans.

DOI: 10.1128/JVI.02449-14
PubMed: 25410860

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000090
to stream PubMed, to step Curation: 000090
to stream PubMed, to step Checkpoint: 000082

Links to Exploration step

pubmed:25410860

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zengel, James" sort="Zengel, James" uniqKey="Zengel J" first="James" last="Zengel">James Zengel</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation>
<country wicri:rule="url">Indonésie</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<wicri:noRegion>Maryland</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25410860</idno>
<idno type="pmid">25410860</idno>
<idno type="doi">10.1128/JVI.02449-14</idno>
<idno type="wicri:Area/PubMed/Corpus">000090</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000090</idno>
<idno type="wicri:Area/PubMed/Curation">000090</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000090</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000082</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000082</idno>
<idno type="wicri:Area/Ncbi/Merge">000B02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zengel, James" sort="Zengel, James" uniqKey="Zengel J" first="James" last="Zengel">James Zengel</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation>
<country wicri:rule="url">Indonésie</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<wicri:noRegion>Maryland</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Cross Protection</term>
<term>Cross Reactions</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Influenza A Virus, H3N8 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Vaccines, Attenuated (administration & dosage)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Vaccines, Attenuated (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Furets</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Protection croisée</term>
<term>Réactions croisées</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H3N8 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins atténués (administration et posologie)</term>
<term>Vaccins atténués (génétique)</term>
<term>Vaccins atténués (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Sous-type H3N8 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H3N8 Subtype</term>
<term>Influenza Vaccines</term>
<term>Orthomyxoviridae Infections</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Cross Protection</term>
<term>Cross Reactions</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Furets</term>
<term>Infections à Orthomyxoviridae</term>
<term>Modèles animaux de maladie humaine</term>
<term>Protection croisée</term>
<term>Réactions croisées</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Equine influenza viruses (EIV) are responsible for rapidly spreading outbreaks of respiratory disease in horses. Although natural infections of humans with EIV have not been reported, experimental inoculation of humans with these viruses can lead to a productive infection and elicit a neutralizing antibody response. Moreover, EIV have crossed the species barrier to infect dogs, pigs, and camels and therefore may also pose a threat to humans. Based on serologic cross-reactivity of H3N8 EIV from different lineages and sublineages, A/equine/Georgia/1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics with the hemagglutinin and neuraminidase genes of the eq/GA/81 wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) vaccine donor virus, which is the backbone of the licensed seasonal live attenuated influenza vaccine. In both mice and ferrets, intranasal administration of a single dose of the eq/GA/81 ca vaccine virus induced neutralizing antibodies and conferred complete protection from homologous wt virus challenge in the upper respiratory tract. One dose of the eq/GA/81 ca vaccine also induced neutralizing antibodies and conferred complete protection in mice and nearly complete protection in ferrets upon heterologous challenge with the H3N8 (eq/Newmarket/03) wt virus. These data support further evaluation of the eq/GA/81 ca vaccine in humans for use in the event of transmission of an equine H3N8 influenza virus to humans.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25410860</PMID>
<DateCompleted><Year>2015</Year>
<Month>04</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>89</Volume>
<Issue>3</Issue>
<PubDate><Year>2015</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.</ArticleTitle>
<Pagination><MedlinePgn>1652-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02449-14</ELocationID>
<Abstract><AbstractText Label="UNLABELLED">Equine influenza viruses (EIV) are responsible for rapidly spreading outbreaks of respiratory disease in horses. Although natural infections of humans with EIV have not been reported, experimental inoculation of humans with these viruses can lead to a productive infection and elicit a neutralizing antibody response. Moreover, EIV have crossed the species barrier to infect dogs, pigs, and camels and therefore may also pose a threat to humans. Based on serologic cross-reactivity of H3N8 EIV from different lineages and sublineages, A/equine/Georgia/1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics with the hemagglutinin and neuraminidase genes of the eq/GA/81 wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) vaccine donor virus, which is the backbone of the licensed seasonal live attenuated influenza vaccine. In both mice and ferrets, intranasal administration of a single dose of the eq/GA/81 ca vaccine virus induced neutralizing antibodies and conferred complete protection from homologous wt virus challenge in the upper respiratory tract. One dose of the eq/GA/81 ca vaccine also induced neutralizing antibodies and conferred complete protection in mice and nearly complete protection in ferrets upon heterologous challenge with the H3N8 (eq/Newmarket/03) wt virus. These data support further evaluation of the eq/GA/81 ca vaccine in humans for use in the event of transmission of an equine H3N8 influenza virus to humans.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Equine influenza viruses have crossed the species barrier to infect other mammals such as dogs, pigs, and camels and therefore may also pose a threat to humans. We believe that it is important to develop vaccines against equine influenza viruses in the event that an EIV evolves, adapts, and spreads in humans, causing disease. We generated a live attenuated H3N8 vaccine candidate and demonstrated that the vaccine was immunogenic and protected mice and ferrets against homologous and heterologous EIV.</AbstractText>
<CopyrightInformation>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baz</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Paskel</LastName>
<ForeName>Myeisha</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Matsuoka</LastName>
<ForeName>Yumiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zengel</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Xing</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Treanor</LastName>
<ForeName>John J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>11</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053123" MajorTopicYN="N">Influenza A Virus, H3N8 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>4</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25410860</ArticleId>
<ArticleId IdType="pii">JVI.02449-14</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.02449-14</ArticleId>
<ArticleId IdType="pmc">PMC4300743</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Bull World Health Organ. 1969;41(3):447-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5309454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2004 Dec;3(6):643-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15606348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2009;154(5):887-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19396578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7(5):659-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23289427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1965 Apr;94:563-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14299031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2008 Mar;14(3):461-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18325262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 1967 Jul;86(1):185-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4951557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Mar 1;199(5):711-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19210163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1993;11(11):1172-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8249440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1994 Feb;38(1):25-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8067310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1965 Apr 3;206:41-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14334358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jun;88(12):7016-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24719414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet J. 2012 Mar;191(3):312-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22178358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Rev Respir Dis. 1961 Feb;83(2)Pt 2:48-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13723557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014;9(1):e85616</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24465622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transbound Emerg Dis. 2015 Dec;62(6):623-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24472362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jun;87(12):6901-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23576512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1958 Jan-Mar;2(1):52-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13533033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Oct;81(19):10558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2014 Feb;59(2):100-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24360918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 May 8;24(19):4047-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16545507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2010 Apr;16(4):699-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20350392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Nov;84(22):11950-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20810733</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Vet Med Assoc. 1963 Sep 15;143:587-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14077956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Rec. 1996 Jan 20;138(3):68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8629334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S25-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7551408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Oct 21;310(5747):482-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16186182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21199945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aust Vet J. 2011 Jul;89 Suppl 1:27-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21711279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Mar;88(5):2867-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24371061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2013 Jun;20(6):867-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23576673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Equine Vet J. 1993 Nov;25(6):537-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8276003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Rec. 1965 Jan 16;77:57-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14330182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Med Int. 2013;2013:874521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24198997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2008 Jun;14(6):902-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18507900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet J. 2011 Jul;189(1):7-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20685140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2001;146(6):1063-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11504416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Jan;83(1):65-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18945773</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Jun 8;27(28):3744-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19464558</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Indonésie</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Maryland</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
</region>
<name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
<name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name>
<name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
<name sortKey="Zengel, James" sort="Zengel, James" uniqKey="Zengel J" first="James" last="Zengel">James Zengel</name>
</country>
<country name="Indonésie"><noRegion><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B02 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000B02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:25410860
   |texte=   A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:25410860" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki